Drugs / Pagibaximab
Pagibaximab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00636285 | Apr → Sep 2001 | bacterial infectious disease with sepsis | Biosynexus Incorporated | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00631878 | Nov 2001 → May 2003 | neonatal sepsis | Biosynexus Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00631800 | May 2003 → Mar 2004 | bacterial infectious disease with sepsis | Biosynexus Incorporated | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00646399 | Mar 2009 → May 2011 | bacterial infectious disease with sepsis | Biosynexus Incorporated | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pagibaximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00646399 ↗ |
| Known as | A-110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108042 ↗ |
| Known as | BSYX-A110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00636285 ↗ |
| Modality | Monoclonal antibody | “A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.” PMID 21788224 ↗ Jul 2011 |
| Route | Intravenous | “Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14” NCT00631800 ↗ |